[go: up one dir, main page]

AR051958A1 - Derivados heterociclicos utiles como moduladores selectivos del receptor de androgeno (sarms) - Google Patents

Derivados heterociclicos utiles como moduladores selectivos del receptor de androgeno (sarms)

Info

Publication number
AR051958A1
AR051958A1 ARP050104794A ARP050104794A AR051958A1 AR 051958 A1 AR051958 A1 AR 051958A1 AR P050104794 A ARP050104794 A AR P050104794A AR P050104794 A ARP050104794 A AR P050104794A AR 051958 A1 AR051958 A1 AR 051958A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
hydrogen
4alkyl
halogenated
Prior art date
Application number
ARP050104794A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR051958A1 publication Critical patent/AR051958A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente se refiere a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de desordenes y trastornos modulados por el receptor de androgeno. Reivindicacion 1: Un compuesto de formula (1), en la cual: W está seleccionado del grupo que consiste en O, S y NRF; donde RF está seleccionado del grupo que consiste en hidrogeno, hidroxi, ciano, alquilo C1-4, alcoxi C1-4 y -SO2-alquiloC1-4; R1 está seleccionado del grupo que consiste en alquilo C1-4 y alquilo C1-4 halogenado; R2 está seleccionado del grupo que consiste en hidrogeno, alquilo C1-4, alquilo C1-4 halogenado, -C(O)O-alquiloC1-4, -C(O)-alquiloC1-4 y -C(O)-(alquilo C1-4 halogenado); a es un numero entero de 0 a 1; la formula (2) está seleccionado del grupo que consiste en fenilo, piridilo, pirazinilo, pirimidinilo y piridazinilo; R3 está ausente o está seleccionado del grupo que consiste en hidrogeno, halogeno, alquilo C1-4, alquilo C1-4 halogenado, ciano, nitro, amino, alquilamino C1-4, di(alquilo C1-4)amino, -O-alquiloC1-4, -S(O)0-2-alquiloC1-4, -NRA-C(O)-alquiloC1-4, bencilo, -O-fenilo, -C(O)-fenilo y -S(O)0-2- fenilo; donde RA está seleccionado entre hidrogeno o alquilo C1-4; R4 está ausente o está seleccionado del grupo que consiste en hidrogeno, halogeno, alquilo C1-4, alquilo C1-4 halogenado, ciano, nitro, amino, alquilamino C1-4, di(alquilo C1-4)amino, -O-alquiloC1-4, -S(O)0-2-alquiloC1-4, -NRB-C(O)-alquiloC1-4, bencilo, -O-fenilo y -S(O)0-2-fenilo; donde Rb está seleccionado de hidrogeno o alquilo C1-4; con la condicion de que cuando la formula (2), es fenilo entonces por lo menos uno de R3 o R4 es distinto de hidrogeno; R6 y R7 están cada uno independientemente ausentes, o están seleccionados del grupo que consiste en hidrogeno, halogeno, alquilo C1-4, alquenilo C2-4, alcoxi C1-4, ciano, -C(O)-alquiloC1-4 y -S(O)0-2-alquiloC1-4; con la condicion adicional de que R3 esté ausente cuando un átomo de nitrogeno está presente en la posicion 3 de formula (2); con la condicion adicional de que R4 esté ausente cuando está presente un átomo de nitrogeno en la posicion 4 de formula (2); con la condicion adicional de que R6 esté ausente cuando está presente un átomo de nitrogeno en la posicion 6 de formula (2); con la condicion adicional de que R7 esté ausente cuando está presente un átomo de nitrogeno en la posicion 2 de formula (2); ôel anillo Aö está seleccionado del grupo que consiste en las formulas (3); donde R5' está seleccionado del grupo que consiste en halogeno y alquilo C1-4; y donde R10 y R11 están cada uno independientemente seleccionados de hidrogeno, alquilo C1-4, bencilo o -C(O)-CF3; R5 está seleccionado del grupo que consiste en hidrogeno, carboxi, alquilo, alquilo C1- 4 halogenado, alquilo C1-4 hidroxi sustituido, cicloalquilo, arilo, aralquilo, heteroarilo, heteroaril-alquil-, heterocicloalquilo, heterocicloalquil- alquil-, -C(O)-alquilo, -C(O)-alquiloC1-4 halogenado, -C(O)O-alquiloC1-4, -C(O)O-arilo, -alquiloC1- 4-S(O)0-2-alquiloC1-4, t-butil-dimetil- sililo y trimetilsililo; donde el arilo, cicloalquilo, heteroarilo o heterocicloalquilo, solo o como parte de un grupo sustituyente, está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo que consiste en halogeno, hidroxi, alquilo C1-4, alcoxi C1-4, alquilo C1-4 halogenado, alcoxi C1-4 halogenado, ciano, nitro, amino, alquilamino C1-4, di(alquilo C1-4)amino, - NRc-C(O)-alquiloC1-4, NRc-C(O)-alquiloC1-4 halogenado, -C(O)O-alquiloC1-4, -S(O)0-2-alquiloC1-4, -SO2-NRCRD, trimetil-sililo y t-butil- dimetil-sililoxi; donde cada uno de RC y RD están independientemente seleccionados entre hidrogeno o alquilo C1-4; o una sal farmacéuticamente aceptable de los mismos.
ARP050104794A 2004-11-16 2005-11-15 Derivados heterociclicos utiles como moduladores selectivos del receptor de androgeno (sarms) AR051958A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62833704P 2004-11-16 2004-11-16
US11/258,448 US7465809B2 (en) 2004-11-16 2005-10-25 Heterocycle derivatives useful as selective androgen receptor modulators (SARMs)

Publications (1)

Publication Number Publication Date
AR051958A1 true AR051958A1 (es) 2007-02-21

Family

ID=36218098

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104794A AR051958A1 (es) 2004-11-16 2005-11-15 Derivados heterociclicos utiles como moduladores selectivos del receptor de androgeno (sarms)

Country Status (10)

Country Link
US (3) US7465809B2 (es)
EP (1) EP1817292B1 (es)
JP (1) JP4969451B2 (es)
CN (2) CN104803916B (es)
AR (1) AR051958A1 (es)
AU (1) AU2005307003B2 (es)
CA (1) CA2587678C (es)
MY (1) MY142048A (es)
TW (1) TWI483725B (es)
WO (1) WO2006055184A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007212191B2 (en) * 2006-02-10 2011-12-22 Janssen Pharmaceutica N.V. Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators
DE102006047617B4 (de) * 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2011097496A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CA3027563C (en) 2016-06-22 2024-07-02 Ellipses Pharma Ltd AR+ METHODS FOR BREAST CANCER TREATMENT
AU2017290705B2 (en) * 2016-06-29 2021-08-26 Rascal Therapeutics, Inc. Compounds and compositions for the treatment of cancer
CN106748884B (zh) * 2016-12-13 2021-08-20 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
WO2018175449A1 (en) 2017-03-21 2018-09-27 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
PH12021551950A1 (en) 2019-02-12 2022-05-23 Radius Pharmaceuticals Inc Processes and compounds
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4015501A1 (en) * 2020-12-16 2022-06-22 Consejo Superior de Investigaciones Científicas (CSIC) N-benzyl-alpha-aminoamides as anaphase-promoting complex/cyclosome (apc/c) inhibitors
CA3214408A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer
WO2024010817A2 (en) * 2022-07-07 2024-01-11 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) o-linked ligands and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022432A1 (en) * 1996-11-18 1998-05-28 Yamanouchi Pharmaceutical Co., Ltd. Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
JP2002527438A (ja) 1998-10-09 2002-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４，５−ジヒドロ−イソオキサゾール誘導体及びそれらの製薬学的使用
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US6738540B2 (en) * 2001-06-22 2004-05-18 Lucent Technologies Inc. Optical cross-connect switch using programmable multiplexers/demultiplexers
US6657770B2 (en) * 2001-06-22 2003-12-02 Lucent Technologies Inc. Programmable optical multiplexer/demultiplexer
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
CN1835937B (zh) * 2003-06-13 2012-07-18 詹森药业有限公司 作为选择性雄激素受体调节剂(sarms)的噻唑啉衍生物
AU2005285035B2 (en) * 2004-09-10 2012-03-22 Janssen Pharmaceutica N.V. Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS)

Also Published As

Publication number Publication date
CN104803916B (zh) 2017-08-11
CN104803916A (zh) 2015-07-29
MY142048A (en) 2010-08-30
EP1817292B1 (en) 2015-04-08
CN101103003A (zh) 2008-01-09
TWI483725B (zh) 2015-05-11
WO2006055184A2 (en) 2006-05-26
AU2005307003A1 (en) 2006-05-26
EP1817292A2 (en) 2007-08-15
JP2008520665A (ja) 2008-06-19
US20060211756A1 (en) 2006-09-21
CA2587678A1 (en) 2006-05-26
CA2587678C (en) 2013-05-21
US20090131365A1 (en) 2009-05-21
TW200621235A (en) 2006-07-01
JP4969451B2 (ja) 2012-07-04
US7781473B2 (en) 2010-08-24
WO2006055184A3 (en) 2007-04-05
AU2005307003B2 (en) 2011-10-13
US7465809B2 (en) 2008-12-16
US20100267670A1 (en) 2010-10-21
US8088811B2 (en) 2012-01-03

Similar Documents

Publication Publication Date Title
AR051958A1 (es) Derivados heterociclicos utiles como moduladores selectivos del receptor de androgeno (sarms)
AR050966A1 (es) Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms)
PE20231190A1 (es) Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de uso
AR065280A1 (es) Agentes antiparasitarios
AR054320A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas
AR055177A1 (es) Compuestos heterociclicos fusionados utiles como moduladores de cinasa
DOP2006000102A (es) Derivados de purina
AR004225A1 (es) Derivados de indolin-2-ona, su uso, un procedimiento para prepararlos, composiciones farmaceuticas que los comprenden y compuestos utiles como intermediarios para preparar dichos derivados
CY1111834T1 (el) Παραγωγα της 4-(2-αμινο-1-hydroxyethyl)phenol σαν αγωνιστικa του αδρενεργικου (adrenergic) ληπτη βητα -2
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
CO4910135A1 (es) Derivados cetolidos 6-0 sustituidos de la eritromicina que tienen actividad bacteriana
DK1817301T3 (da) Forstærkere af glutamat-receptorer
TW200635931A (en) 2,4(4,6)pyrimidine derivatives
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
PE20110582A1 (es) Arilciclohexileteres de dihidro-tetraazabenzoazuleno
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR043055A1 (es) Derivados de 1-(4-benzil-piperazin-1-il)-3- fenil-propenona
DK1643984T3 (da) Anvendelse af parthenolidderivater som antileukæmiske og cytotoksske midler
EA200701233A1 (ru) Производные хиназолина в качестве mtki
AR050967A1 (es) Derivados de bencimidazol utiles como moduladores de los receptores androgenicos (sarms)
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet
AR051989A1 (es) Derivados de quinolina como agentes antibacterianos
CR9092A (es) Metabolitos de ciertos derivados de [1,4]diazepino [6,7,1-ij]quinolina y metodos de preparacion y uso de los mismos

Legal Events

Date Code Title Description
FC Refusal